Adjunct prednisone in community-acquired pneumonia: 180-day outcome of a multicentre, double-blind, randomized, placebo-controlled trial
Claudine A. Blum, Eva A. Roethlisberger, Nicole Cesana-Nigro, Bettina Winzeler, Nicolas Rodondi, Manuel R. Blum, Matthias Briel, Beat Mueller, Mirjam Christ-Crain, Philipp Schuetz · 2023
Read Adjunct prednisone in community-acquired pneumonia: 180-day outcome of a multicentre, double-blind, randomized, placebo-controlled trial by Claudine A. Blum, Eva A. Roethlisberger, Nicole Cesana-Nigro, Bettina Winzeler, Nicolas Rodondi, Manuel R. Blum, Matthias Briel, Beat Mueller, Mirjam Christ-Crain, Philipp Schuetz (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10712075.txt.
Description
Claudine Blum and co-authors report long-term results from a trial of added steroid care for lung infection caught outside hospitals, in work from 2023. Short-term gains from steroids in this illness are known, but health effects months later were unsure. The team followed trial patients to six months.
The trial had enrolled 785 adults in hospital, split by chance between steroid and dummy pills, with neither side knowing which. At six months, 727 patients could be checked. Death rates by that point did not differ between groups. The team also tracked returns to hospital, repeat lung infections, new infections, and new blood pressure or insulin needs. The report weighs whether short-term gains carry hidden late costs.
Catalog record
| CREATOR | Claudine A. Blum, Eva A. Roethlisberger, Nicole Cesana-Nigro, Bettina Winzeler, Nicolas Rodondi, Manuel R. Blum, Matthias Briel, Beat Mueller, Mirjam Christ-Crain, Philipp Schuetz |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |